A major study from Denmark found that women with diabetes who used GLP-1 receptor agonists like semaglutide around the time of conception had a significantly higher risk of preterm birth, but this risk did not apply to women using these medications for weight management alone. The findings, published in Human Reproduction Open, raise important questions about medication timing for women with diabetes who are planning pregnancies. What Did the Research Actually Find? Researchers at Copenhagen University Hospital Hvidovre analyzed data from 756,636 singleton pregnancies among 480,231 women in Denmark. Of these pregnancies, 529 involved periconceptional exposure to GLP-1 receptor agonists, which are medications taken around the time of conception. The study examined whether these drugs increased the risk of obstetric complications. The results showed a clear pattern: women using GLP-1 receptor agonists for diabetes treatment had elevated preterm birth risk, with adjusted odds ratios of 1.70 for liraglutide and 1.84 for semaglutide. This means women using semaglutide were roughly 84% more likely to deliver preterm compared to women not using the medication. However, women taking these same medications specifically for weight management showed no increased preterm birth risk. "We found that these medications were associated with an increased risk of preterm birth, but the risk was only present when the medication was used for diabetes treatment, and not for weight management. This suggests that the underlying condition of diabetes, rather than the medication, may be driving this association," stated Kathrine Vauvert R. Hviid, researcher at Copenhagen University Hospital Hvidovre. Kathrine Vauvert R. Hviid, Copenhagen University Hospital Hvidovre Why Does Diabetes Status Matter More Than the Drug Itself? The distinction between diabetes-related use and weight-loss use is crucial. The research suggests that uncontrolled diabetes during pregnancy, rather than the medication itself, may be the primary driver of preterm birth risk. Diabetes during pregnancy creates metabolic stress on both mother and fetus, and this underlying condition could explain the increased complications seen in the study. This finding is reassuring for women without diabetes who are using GLP-1 medications like Wegovy for weight management. However, it underscores the complexity of managing diabetes while planning pregnancy. Women with diabetes need individualized care that balances blood sugar control with pregnancy safety. What Should Women with Diabetes Do When Planning Pregnancy? If you have diabetes and are considering pregnancy, medication timing becomes critical. Current medical guidance recommends discontinuing Wegovy at least two months before attempting conception to allow the medication to clear your system. For women with diabetes, the conversation with healthcare providers should focus on transitioning to pregnancy-safe alternatives that maintain blood sugar control without the potential preterm birth risk. - Medication Review: Women with diabetes should discuss their current GLP-1 medications with their doctor at least three months before attempting conception to explore safer alternatives for blood sugar management during pregnancy. - Blood Sugar Monitoring: Tight glycemic control before and during pregnancy reduces complications, so women may need to switch to medications with longer safety data in pregnancy, such as insulin or metformin. - Prenatal Counseling: Specialized prenatal care for women with diabetes can help coordinate medication changes and ensure both mother and baby receive optimal support throughout pregnancy. What About Wegovy and Other Weight-Loss Medications During Pregnancy? The safety picture for weight-loss medications during pregnancy is different from diabetes management. Animal studies of semaglutide showed concerning results, including 1.5 times higher pregnancy loss rates in exposed groups compared to control animals, plus potential skeletal malformations during critical organ development periods. While these are animal studies and don't automatically predict human outcomes, they've prompted medical experts to recommend caution. The medication's appetite-suppressing effects may also reduce maternal weight gain, which can impact fetal growth and development. Adequate maternal nutrition and appropriate weight gain are essential for supporting the rapid cellular division and organ development that occurs during pregnancy. When mothers experience significant appetite reduction from weight-loss medications, it may compromise the nutritional foundation necessary for healthy fetal growth. For women taking Wegovy who become unexpectedly pregnant, immediate medical consultation is essential. Early exposure doesn't automatically mean problems will occur, but healthcare providers can monitor the pregnancy more closely and provide appropriate guidance based on timing and duration of exposure. What Are Safe Alternatives for Weight Management During Pregnancy? Pregnancy weight management doesn't require pharmaceutical intervention to be effective. Several evidence-based approaches can help maintain healthy weight gain patterns without medication risks. - Dietary Counseling: Registered dietitians specializing in prenatal nutrition can provide meal planning, portion management, and nutritional education tailored to pregnancy needs, supporting both maternal health and fetal development. - Prenatal Exercise Programs: Controlled fitness options designed specifically for pregnant women provide cardiovascular benefits, strength maintenance, and stress reduction without the potential complications of weight-loss medications. - Behavioral Therapy: Addressing underlying eating patterns and emotional relationships with food provides sustainable weight management strategies that extend beyond pregnancy and support long-term health. What About Other GLP-1 Medications Like Ozempic and Mounjaro? The preterm birth risk identified in this study applies to GLP-1 receptor agonists as a class, which includes semaglutide (Ozempic, Wegovy), liraglutide, and tirzepatide (Mounjaro). Women taking any of these medications who are planning pregnancy should have detailed conversations with their healthcare providers about timing and alternatives. The same two-month discontinuation period recommended for Wegovy applies to these other medications as well. For women with diabetes specifically, the challenge is finding medications that control blood sugar effectively without the preterm birth risk. This requires coordinated care between obstetrics and endocrinology specialists who can develop a personalized transition plan. The Bottom Line for Women Planning Pregnancy The key takeaway is nuanced: GLP-1 medications appear to increase preterm birth risk primarily in women with diabetes, likely because diabetes itself creates metabolic stress during pregnancy. Women without diabetes using these medications for weight loss alone don't show the same increased risk, though animal studies suggest caution is warranted. Regardless of why you're taking a GLP-1 medication, planning pregnancy requires stopping the medication well in advance and working with healthcare providers to develop a safe transition plan. The good news is that safe, effective alternatives exist for both blood sugar management and weight control during pregnancy, and medical teams can help you navigate this important transition.
